RSS   Newsletter   Contact   Advertise with us

Sanifit appoints Preston S. Klassen chief medical officer

Staff writer | Palma de Mallorca, Spain | June 8, 2016
SanifitJune 8, 2016, Palma de Mallorca, Spain - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company, announces the appointment of Preston S. Klassen as its chief medical officer.
Dr. Klassen brings nearly 14 years of industry experience to Sanifit and five years prior to this in Nephrology as a faculty member at Duke.

In addition to his CMO role within the company, Dr. Klassen will serve as President of the US subsidiary and his primary responsibilities will include leading the clinical development of SNF472 and enhancing the Company’s growing presence in the US.

Dr. Klassen was most recently Executive Vice President, Head of Global Development at Orexigen Therapeutics. Previously, Dr Klassen held several positions of increasing responsibility at Amgen, Inc., including Therapeutic Area Head for Nephrology.

Prior to joining Amgen, he was a faculty member in the Division of Nephrology at Duke University Medical Center from 1997 to 2002.

Dr. Klassen received his M.D. from the University Of Nebraska College Of Medicine and completed his residency in Internal Medicine, fellowship in Nephrology, and M.H.S. degree at Duke University.

The announcement follows the recent appointment of Keith R. Leonard, Former President & CEO of Kythera Biopharmaceuticals, to Sanifit’s Board of Directors.